Neovascular Glaucoma
Conditions
Brief summary
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).
Interventions
Administration by intravitreal injection
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosis of NVG * Patients who have received IVT-AFL treatment according to Japanese labeling.
Exclusion criteria
* Patients who are contraindicated based on approved label * Diagnosis of other indication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of participants with adverse events (AEs) | Up to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular Pressure (IOP) value after study drug administration | Up to 6 months | In case of transient and/or persistent IOP elevation |
| Mean changes in Visual Acuity | Up to 6 months | — |
| Proportion of participants with improvement of anterior neovascularization | Up to 6 months | — |
Countries
Japan
Contacts
CONTACTBayer Clinical Trials Contact
Outcome results
None listed